More Could Benefit from HIV Prevention Pill Truvada

Too few Americans who are at risk for HIV infection are taking Truvada — a daily pill that could protect them against the virus that causes AIDS, federal health officials report.

Health care providers must help boost patient awareness and use of the drug, health experts stressed.

About 25 percent of sexually active gay and bisexual adult men, 20 percent of injection drug users, and less than 1 percent of sexually active heterosexuals are at high risk for HIV infection, according to the U.S. Centers for Disease Control and Prevention’s Vital Signs report. People in these groups need to know about Truvada, which is also known as the pre-exposure prophylaxis (PrEP) pill, the government experts said.

Taken daily, the PrEP pill can reduce the risk of sexually acquired HIV by more than 90 percent. The PrEP pill can reduce injection drug users’ risk of HIV by more than 70 percent, the experts said.

However, recent data suggests some primary care health providers have never heard of PrEP, which was approved by the U.S. Food and Drug Administration in 2012. The full potential of the drug to prevent HIV infections can only be achieved by increasing awareness of the drug and providing counseling for those

December 10th, 2015|Categories: Men's Health, Research|

New CDC Report Shows High Percentage for PrEP Indications for MSM

Last week, the CDC’s Morbidity and Mortality Weekly Report (MMWR) released estimated percentages and numbers of adults with indications for PrEP. Among adult MSM aged 18-59 years in the United States who report sexual activity in the past year, approximately 25% have indications for PrEP to prevent HIV acquisition, compared with approximately 18% of persons who inject drugs and 0.4% of heterosexually active adults.

The high percentage of MSM with PrEP indications is consistent with the high number of new HIV infections among MSM. The high percentage of persons who inject drugs with PrEP indications reflects the relatively high percentage who report using a needle after it was used by another injector. The low percentage and high absolute number of heterosexually active adults is a reflection of the large heterosexually active U.S. population and the low rate of new HIV diagnoses in these adults. The actual risk for acquiring HIV infection for each of these transmission risk groups differs based on efficiency of transmission routes and likelihood of exposure to HIV.

See more about the research here.

December 10th, 2015|Categories: Men's Health, PrEP, Research|

Gonorrhea Study

Did you know that each year, more than 700,000 people in the U.S. will get a gonorrhea infection? Gonorrhea is an infection caused by a bacteria spread by sexual contact. Symptoms include a green, yellow or white discharge from the penis or vagina, a burning feeling when urinating or in the throat, and pain in the pelvis or testicles.

Usually, Gonorrhea can easily be treated with antibiotic medications. However, some strains are becoming resistant to the currently used medications. Because of this, new antibiotics must be developed to treat this ever-changing bacteria.

If you suspect that you may have Gonorrhea, you may qualify for a research trial that is studying a new treatment option. Qualified participants are treated free of charge, and will be compensated for their time and participation. Call Mills Clinical Research at 310-550-2271.

July 13th, 2015|Categories: Research|

PrEP Research Study

The Men’s Health Foundation is conducting an investigator sponsored research study, “PUMP” ( PrEP in Urban Medical Primary Care).  It is a non-randomized, unblinded, retrospective and prospective analysis of  PrEP.  (The Southern California Men’s Medical Group, the clinical arm of Men’s Health Foundation, is one of the largest private prescribers of Truvada for PrEP in the US). The study goal is to evaluate real world retrospective and prospective PrEP data in a high capacity, urban primary and specialty care clinic of 300 MSM patients prescribed PrEP.

The Men’s Health Foundation has received funding to conduct a research study regarding PrEP. While the effectiveness of PrEP is no longer an issue to dispute, there is still a need for more data. Because most of the information that we have about PrEP comes from highly controlled and closely monitored clinical trials, it’s necessary to collect data about how PrEP will work in a real-world setting. The Men’s Health Foundation will be conducting a two-part PrEP study, which will include retrospective and prospective data collection.

The retrospective PrEP study will evaluate the outcomes of up to 300 past clinic patients who were prescribed PrEP. The study will seek information about how patients took PrEP, whether

July 13th, 2015|Categories: PrEP, Research|